PYY3-36 produced an initial appetite-suppressing effect followed by a delayed appetite-stimulating rebound in mice, unlike GLP-1 which only suppressed — explaining why PYY-based obesity drugs may have limited duration of effect.
Key findingPYY3-36 injection produced biphasic appetite response: acute anorexia followed by delayed orexigenic rebound, unlike GLP-1 which showed sustained anor
What the researchers found
PYY3-36 injection produced biphasic appetite response: acute anorexia followed by delayed orexigenic rebound, unlike GLP-1 which showed sustained anorexia — this rebound effect may limit PYY3-36's obesity drug potential compared to GLP-1 agonists.
Why it matters
Relevant for neuropeptides, weight-loss.
How the study worked
animal-study study.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
PYY3-36 injection in mice produces an acute anorexigenic effect followed by a delayed orexigenic effect not observed with other anorexigenic gut hormones.
American journal of physiology. Endocrinology and metabolism, 294(4), E698-708
Citation
Parkinson, James R C; Dhillo, Waljit S; Small, Caroline J; Chaudhri, Owais B; Bewick, Gavin A; Pritchard, Iain; Moore, Stanley; Ghatei, Mohammed A; Bloom, Stephen R. (2008). PYY3-36 injection in mice produces an acute anorexigenic effect followed by a delayed orexigenic effect not observed with other anorexigenic gut hormones.. American journal of physiology. Endocrinology and metabolism, 294(4), E698-708. https://doi.org/10.1152/ajpendo.00405.2007